IPP Bureau
Bayer’s Sevabertinib granted FDA priority review for the treatment of patients with HER2-mutant non-small cell lung cancer
By IPP Bureau - May 29, 2025
This is specifically for the evaluation of medicines that, if approved, would provide a significant improvement in the safety or effectiveness of the treatment, prevention, or diagnosis of a serious condition
Pimicotinib demonstrates best-in-class potential with significant efficacy and clinically meaningful improvements in patients with tenosynovial giant cell tumor
By IPP Bureau - May 29, 2025
MANEUVER met all five key secondary endpoints, with statistically significant and clinically meaningful improvements in pain, stiffness, range of motion, physical function, and decrease in tumor volume
USV’s ‘United for BP Control’ Mission takes aim at India’s blood pressure epidemic
By IPP Bureau - May 29, 2025
The initiative was announced at World Hypertension Congress, Chennai
Zydus receives USFDA ‘Fast Track Designation’ for novel oral inhibitor ‘Usnoflast’
By IPP Bureau - May 29, 2025
Usnoflast has previously also received ‘Orphan Drug Designation (ODD)’ from the USFDA
Granules India posts Q4 FY25 PAT at Rs. 152 Cr
By IPP Bureau - May 28, 2025
The company reported sustained increase in formulations' share despite slowdown in productivity of Gagillapur facility
Kerala Ayurveda reports FY25 consolidated revenue higher by 22% at Rs. 137.2 Cr
By IPP Bureau - May 28, 2025
Adjusted EBITDA positive at Rs. 3.1 crore despite investments in marketing, talent hiring and technology over the year
Sanjivani Paranteral posts Q4 FY25 at Rs. 2.19 Cr
By IPP Bureau - May 28, 2025
For FY25, Revenue from operation grew 28.8 per cent YoY to Rs. 70.1 crore
Fluor-built Bayer cell therapy facility in California achieves LEED v4 platinum certification
By IPP Bureau - May 28, 2025
Facility also named 2025 ISPE Facility of the Year Winner for Social Impact - Unmet Medical Needs
Aurobindo Pharma Q4 PAT falls marginally to Rs. 903 Cr
By IPP Bureau - May 27, 2025
During the quarter, US formulations revenue increased by 13.5 per cent YoY to Rs. 4,072 crore
Zydus Lifesciences’ ‘breast cancer awareness campaign reaches millions
By IPP Bureau - May 27, 2025
Campaign empowers women to prioritise their health through thought provoking films, influencer-led campaigns, scientific and medical podcasts, survivor experiences, and digital awareness
Sun Pharma Q4 FY25 revenue up 8.5% to Rs. 12,815 Cr
By IPP Bureau - May 27, 2025
Net profit for the?quarter came in at Rs. 2,889.1 crore, up 4.8 per cent from the year earlier, adjusted for exceptional items
Akums reports Q4 FY25 with 12.4% revenue growth
By IPP Bureau - May 27, 2025
Akums invested Rs. 272 crore in capital expenditure during FY25
Biocon Biologics receives MHRA, UK approval for biosimilar YESINTEK
By IPP Bureau - May 26, 2025
YESINTEK is indicated for the treatment of adults and children from the age of 6 years and olde
Kilitch Drugs posts consolidated Q4 FY25 PAT at Rs. 10.21 Cr
By IPP Bureau - May 26, 2025
The company recorded its quarterly consolidated revenue from operations at Rs. 61.22 crore in Q4 FY25
